In Vivo and Ex Vivo
We are currently developing and testing several products for the early detection of cancer, both in the body (in vivo) and in tissue samples (ex vivo).
The sensitivity limit that we have now shown for our present in-vivo clinical system is ~100,000 cells, making it orders of magnitude more sensitive than current techniques, such as MRI, PET, or mammography.
In addition, our technologies allow us to detect cancer in tissue biopsies, such as bone marrow aspirations, with high sensitivity and specificity. The top figure shows leukemia cells that have been targeted with our antibody-linked nanoparticles. In this figure, the nanoparticleshave been stained blue and are clearly bound to cancer cells, but not significantly bound to normal (pink) cells. Below is a transmission electron micrograph of a leukemia cell with nanoparticlesattached through an antibody to CD34 (a common leukemia marker).
Products
